@article{article, title = {{A phase 3, randomized, open-label, multicenter, global study of the efficacy and safety of durvalumab (D) + tremelimumab (T) + enfortumab vedotin (EV) or D + EV for neoadjuvant treatment in cisplatin-ineligible muscle-invasive bladder cancer (MIBC) (VOLGA).}}, publisher = {{American Society of Clinical Oncology (ASCO)}}, url = {{}}, year = {{2022}}, month = {{2}}, author = {{Powles T and Drakaki A and Teoh JY-C and Grande E and Fontes-Sousa M and Porta C and Wu E and Goluboff ET and Ho S and Hois S and Gupta AK et al}}, doi = {{10.1200/jco.2022.40.6_suppl.tps579}}, volume = {{40}}, journal = {{Journal of Clinical Oncology}}, issue = {{6_suppl}}, pages = {{TPS579-TPS579}}, note = {{Accessed on 2025/05/24}}}